This Long/Short Cannabis Investing Strategy Can Help Your Portfolio Get High Without the Hangover

Canopy Growth Corp. (TSX:WEED) and Aurora Cannabis Inc. (TSX:ACB) are two hot pot stocks. Here’s why I’d short one, and go long the other.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Not only do pot stocks have questionable valuations, but they could also blow up and wipe out your wealth very suddenly. Depending on the actionable negative development, you may not even have the chance to dump your shares if shareholders are stampeding to the exits, thereby overwhelming and potentially bringing down various discount brokerages that can’t handle massive trading volume surges.

You’re essentially risking your entire principal on a security that may or may not surge in price. For many, the risks are just too high to get involved in the Canadian “green rush,” but for those who smell opportunity and not just marijuana smoke, here are a few strategies that may mitigate the risk you’ll end up taking on.

Consider the following long/short strategy:

With recent the recent series of developments, I think now is a great time to buy Canopy Growth Corp. (TSX:WEED) while you take a short position in Aurora Cannabis Inc. (TSX:ACB).

Why?

Not only will you be hedged from downside from negative developments that affect the broader industry, but you’ll also be able to capitalize on what I believe will be a widening of the market cap gap between Canopy and Aurora.

Aurora’s shareholder-dilutive M&A spree is short-worthy!

You’ve probably noticed that Aurora Cannabis stock has been making up for lost time in its 2017 end-year rally, where shares nearly quintupled over the course of a few months after going parabolic. Aurora was the hottest pot stock out there, but since hitting the peak, shares have fallen over 40% thanks in part to questionable M&A activities.

Many pundits are calling for the industry to consolidate, but I believe Aurora is jumping into the pool without checking to see if it’s been filled with water yet. Aurora made multiple acquisitions at absurd multiples when the industry was trading near all-time highs.

Sure, the industry will eventually consolidate, but it’s going to be over the course of many years, not a few months. And the firms that pick up targets at a fair value will be the ones that will come out on top when all is said and done, not the ones that are the quickest to act and are willing to pay up hand over fist.

It looks to me like Aurora’s management team is failing to consider the real value that acquisitions will add relative to their hefty price tags. Shareholders are getting severely diluted in the process, and after the recent $3.2 billion all-stock deal for MedReleaf Corp. (TSX:LEAF), many analysts and investors are becoming increasingly skeptical over management’s strategy, which looks to be drawing comparisons to the reckless “pay any price” M&A spree exhibited by Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) during the Michael Pearson era.

Canopy CEO takes shots at acquisition-hungry peers

In a televised interview conducted by BNN Bloomberg, Canopy CEO Bruce Linton also noted that such M&A activities are like “paying a dollar to get a dime.” Canopy hasn’t been incredibly active on the acquisition lately, and has instead focused on organic growth initiatives. I praised Canopy for its M&A inactivity recently in a previous piece published on April 20, 2018.

While many pundits would agree that the first year of legalization will experience a marijuana shortage, I think the magnitude of the shortage touted by the public is exaggerated and fails to consider the role of a grow-it-yourself black market with personal growth regulations easing in conjunction with higher legal pot prices.

Today, Canadians pay $6.83 per gram of marijuana on average.

Finance Minister Bill Morneau estimated that the cost will rise to about $10 per gram with taxes slapped on, so with little evidence suggesting a rise in recreational usage, I think Aurora’s rushed capacity ramp-up may be in jeopardy. As such, I think shares of Aurora could continue to fall, even after dipping over 40% from its peak.

Given that Canopy possesses the more conservative strategy, I believe its shares will stand to get hit to a lesser degree than that of Aurora shares, which could absolutely implode come the next industry-wide downturn.

I think Aurora really shot themselves in the foot with its recent barrage of expensive deals, and would thus encourage investors to short Aurora while going long Canopy.

Stay hungry. Stay Foolish.

Should you invest $1,000 in CGI Group right now?

Before you buy stock in CGI Group, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and CGI Group wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,058.57!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 38 percentage points since 2013*.

See the Top Stocks * Returns as of 2/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Investing

a person watches a downward arrow crash through the floor
Dividend Stocks

Buy the Dip: 3 TSX Stocks Trading at Bargain Prices Today

These three TSX stocks might be near 52-week lows, but don't let that stop you from making a long-term investment.

Read more »

Person holding a smartphone with a stock chart on screen
Investing

The Best Stocks to Invest $25,000 in Right Now

Given the uncertain outlook, these three Canadian stocks would be ideal additions to your portfolio.

Read more »

Caution, careful
Dividend Stocks

Sell-Off Alert: Why These TSX Blue-Chip Stocks Look Undervalued Now

These TSX stocks look mighty valuable right now, and come with outlooks that make each prime for the picking.

Read more »

dividends can compound over time
Dividend Stocks

Want a 6% Yield? 3 TSX Stocks to Buy Today

These TSX stocks offer yield of over 6% and are well-positioned to sustain their payouts and maintain consistent dividend payments.

Read more »

clock time
Dividend Stocks

10 Years From Now, You’ll Be Glad You Bought These Magnificent TSX Dividend Stocks 

A decade from now, these 2 dividend stocks could give you strong returns through dividends or capital appreciation, or both.

Read more »

Asset Management
Tech Stocks

Missing Out Is Costly: Why the Smartest Investors Keep Buying Canadian Stocks

Smart investors know that success in the stock market comes from identifying high-quality businesses and holding them for a long…

Read more »

A person looks at data on a screen
Energy Stocks

Enbridge Stock vs. Cameco: Which One Is a Better Buy on the Dip?

Consider Enbridge (TSX:ENB) and another great momentum play to energize your TFSA.

Read more »

Silver coins fall into a piggy bank.
Dividend Stocks

TFSA: 3 Top-Tier TSX Stocks for That $7,000 Contribution

The market is full of great long-term stock to fuel your TFSA. Here’s a look at three top-tier TSX stocks…

Read more »